6 results about "Mycobacterium bovis" patented technology

The invention discloses an application of a small molecule drug ATWLPPR Peptide TFA in resisting mycobacterium bovis infection, and belongs to the field of biological medicine, the small molecule drug ATWLPPR Peptide TFA is an agonist of a target host factor NRP1, and then the inhibition effect of the ATWLPPR Peptide TFA on mycobacterium bovis in vitro and in vivo is researched. An in-vitro bacterial loading titration result shows that the ATWLPPR Peptide TFA treatment can present dose-dependent inhibition of the mycobacterium bovis to adhere to A549 cells. Mouse experiment results show that ATWLPPR Peptide TFA treatment can inhibit mice from being infected with mycobacterium bovis, pathological injuries of mouse lung tissues are effectively relieved, and a brand new direction is provided for prevention and control of mycobacterium bovis.

The application provides an sgRNA, a kit, a detection method and application for detecting tuberculosis based on RPA-CRISPR Cas12b technology, and belongs to the technical field of molecular detection. The application provides an sgRNA for detecting mycobacterium, which comprises sgRNA-6110 with a nucleotide sequence as shown in SEQ ID NO: 1 and / or sgRNA-1081 with a nucleotide sequence as shown in SEQ ID NO: 2. The sgRNA can specifically recognize and combine with the high-conservation target sequence IS6110 and IS1081 of Mycobacterium tuberculosis and / or Mycobacterium bovis, and can be used for instant detection of Mycobacterium tuberculosis and / or Mycobacterium bovis which are pathogenic bacteria of human and livestock tuberculosis.

The invention relates to the technical field of microbiological detection, in particular to a Brucella bovis and Mycobacterium bovis dual-fluorescent microsphere test strip and a preparation method and application thereof, and the Brucella bovis and Mycobacterium bovis dual-fluorescent microsphere test strip comprises a bottom plate, a sample pad, a nitrocellulose membrane coated with recombinant protein and absorbent paper, the nitrocellulose membrane coated with the recombinant protein is provided with a brucella abortus lipopolysaccharide detection line T1, a mycobacterium bovis rMPB70 protein detection line T2 and a recombinant streptococcus G (rSPG) protein control line C, and the brucella abortus lipopolysaccharide detection line T1, the mycobacterium bovis rMPB70 protein detection line T2 and the rSPG protein control line C are arranged in parallel. The detection time is short, the stability is good, the operation is simple, the sensitivity is high, complex instruments and professional personnel are not needed, and the result judgment is visual and reliable.

The application discloses a preparation method of a mycobacterium bovis polysaccharide antigen, the polysaccharide antigen is a glycosyl part of a phenolic glycolipid PGL in a cell wall of mycobacterium bovis, the polysaccharide antigen has a clear and single chemical structure, can be prepared in a large scale and efficiently through a chemical synthesis method, and effectively solves problems of a complex natural extraction process, non-uniform structure, limited yield and the like. The polysaccharide antigen can be used as a core immunogen and is used for preparation of a mycobacterium PGL polysaccharide conjugate vaccine, provides a stable and controllable key raw material for tuberculosis vaccine research and development, and has a good industrial application prospect.

There is provided a skin test diagnostic reagent comprising: at least one 40mer polypeptide consisting of any one of SEQ ID NOs: 1, 3 or 4; at least one 40mer polypeptide consisting of any one of SEQ ID NOs: 7 or 8; and at least one 40mer polypeptide consisting of any one of SEQ ID NOs: 10, 11 or 12, characterised in that the reagent elicits a positive result when administered in a skin test to an animal infected with Mycobacterium bovis or Mycobacterium tuberculosis.

This invention discloses a plant pta The study of gene-inactivated BCG mutant strains and their applications falls under the fields of biotechnology and infectious disease prevention and control. Mutant strain B494 (accession number CCTCC NO.M 20253064) was obtained through screening a random insertion mutant library of Mycobacterium bovis BCG. Identification revealed that the mutation occurred in... pta The gene (SEQ ID NO.1), inactivation of which leads to impaired bacterial energy metabolism, intracellular acidification, decreased tolerance to environmental stress, and reduced survival and proliferation capacity within macrophages. This invention discloses... pta Genes play a central role in regulating mycobacterial metabolism and virulence. The mutant strain B494 exhibits significant attenuated characteristics and can serve as a candidate strain for novel attenuated live tuberculosis vaccines or for screening anti-tuberculosis drugs that regulate metabolism.